Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients".

NCT01663116 is registered in ClinicalTrials.gov with Tigenix S.A.U. as lead sponsor.

NCT NCT01663116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01663116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients".
Lead sponsor
Tigenix S.A.U.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2011
Completion date
January 31, 2013
Enrollment
53 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis aggravated